# Modeling neurovascular dysfunction in Alzheimer’s disease using an isogenic brain-chip model

## TL;DR

Researchers created a brain-chip model using stem cells to study Alzheimer’s disease, showing dysfunction in blood-brain barrier and inflammation.

## Contribution

A novel brain-chip model using isogenic hiPSCs reveals AD-related neurovascular dysfunction and vascular tau accumulation.

## Key findings

- AD brain-chips showed reduced claudin-5 and ZO-1 expression with increased paracellular permeability.
- AD brain-chips had decreased P-glycoprotein activity and altered Aβ42 and tau levels in different channels.
- Increased proinflammatory markers IL-6 and MCP-1 were observed in AD brain-chips.

## Abstract

The pathology of Alzheimer’s Disease (AD) is characterized by aggregates of amyloid beta (Aβ) peptides and neurofibrillary tau tangles. Increased blood-brain barrier (BBB) permeability and reduced Aβ clearance, which signal neurovascular dysfunction, have also been proposed as early markers of AD. Despite intense scrutiny, the mechanisms of AD remain elusive and novel treatments that address core symptoms of dementia are limited. New alternative methods (NAMs) aim to develop in-vitro translational models that recapitulate human pathology more accurately than previous models and could contribute to the development of new therapies.

Here, we developed a NAM model of the cortical neurovascular unit (NVU) using brain cells derived from human induced pluripotent stem cells (hiPSCs) from a patient with AD and a healthy individual. Differentiated neurons, astrocytes, pericytes, microglia, and brain-like microvascular endothelial cells were cultured in a microphysiological system to create a brain-chip model to evaluate NVU-related endpoints.

Compared to control, AD brain-chips had reduced claudin-5 and ZO-1 expression and increased paracellular permeability. AD brain-chips also had decreased activity of the efflux transporter P-glycoprotein (P-gp), but its expression was unchanged. In AD brain-chips, levels of Aβ42, total tau, and p-tau 181 were decreased in protein lysates from the brain channel, while levels of total tau and p-tau 181 were increased in protein lysates from the vascular channel. Finally, AD brain-chips had increased levels of the proinflammatory markers IL-6 and MCP-1 in effluent from both brain and vascular channels.

In this brain-chip model, we showed Aβ-independent NVU dysfunction that was related to neuroinflammation and vascular tau accumulation. This study demonstrates the utility of the brain-chip model to evaluate changes in NVU functions induced by AD-like pathology and highlights donor-specific responses associated with the use of hiPSC-derived models.

The online version contains supplementary material available at 10.1186/s12987-025-00708-y.